Claims Quiz

 

Vapotherm high velocity therapy may reduce ED to ICU admissions

• TRUE

• FALSE

Vapotherm high velocity therapy may help reduce/avoid intubations

• TRUE

• FALSE

 

Vapotherm high velocity therapy has been clinically demonstrated to be comparable to NiPPV in treating patients in Type I and Type II respiratory failure.​

• TRUE

• FALSE

Randomized clinical trials show efficacy equivalent to nCPAP and NiPPV for primary support of RDS (in neonates)

• TRUE

• FALSE

Vapotherm is the only system shown to be as clinically effective as CPAP/Bi-Level and NiPPV in preventing intubations in preterm infants with RDS.

• TRUE

• FALSE

High velocity therapy eliminates the requirement for Mechanical Ventilation in COVID-19 patients

• TRUE

• FALSE

As demonstrated by clinical research, the clinically effective flow range in Vapotherm high velocity therapy in Adult patients is 25-35 L/min

• TRUE

• FALSE

Vapotherm high velocity therapy is a safe and efficacious mask-free alternative to CPAP  for neonates.

• TRUE

• FALSE

A subgroup analysis of patients with a ADHF/CHF diagnosis at discharge found that there was no difference in the efficacy of treatment or risk for intubation between NiPPV and Vapotherm high velocity therapy (when treating respiratory distress)

• TRUE

• FALSE

Vapotherm high velocity therapy works by delivering high velocity gas flows to flush the upper airway anatomical dead space of end-expiratory CO2, so an open system for flush is important.

• TRUE

• FALSE